Cabaletta Bio, Inc. Common Stock (CABA) is a publicly traded Healthcare sector company. As of May 21, 2026, CABA trades at $3.44 with a market cap of $536.45M and a P/E ratio of -1.62. CABA moved +5.20% today. Year to date, CABA is +56.36%; over the trailing twelve months it is +82.98%. Its 52-week range spans $0.99 to $5.46. Analyst consensus is strong buy with an average price target of $13.94. Rallies surfaces CABA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cabaletta Presents 50% PC-Free Rese-cel Response, Secures 10-Year Supply Deal: Cabaletta Bio presented six-to-nine-month PC-free data showing 50% drug-free clinical responses in four pemphigus vulgaris patients treated with the lowest rese-cel dose and demonstrated comparable CAR T expansion in two Cellares-manufactured doses. The company also secured a 10-year Cellares supply agreement and aims for a 2027 BLA submission in myositis.
| Metric | Value |
|---|---|
| Price | $3.44 |
| Market Cap | $536.45M |
| P/E Ratio | -1.62 |
| EPS | $-2.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.46 |
| 52-Week Low | $0.99 |
| Volume | 588 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-167.86M |
| Gross Margin | 0.00% |
8 analysts cover CABA: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.94.